OR51E2 and neoplasm: However, the simultaneous induction of a parallel pathway is possible, since Rodriguez et al. (2014) and Sanz et al. (2014) demonstrated a promoted tumor progression via the paralogous receptor PSGR in vivo, involving another signaling pathway than p38 MAPK.